Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Prexasertib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 known ✓ | O14757 | 19/20 | 1.00 |
| ▸ | CHEK2 known ✓ | O96017 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 15/20 | 1.00 |
| ▸ | NUAK1 | O60285 | 1/20 | 1.00 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 1.00 |
| ▸ | FLT3 | P36888 | 1/20 | 1.00 |
| ▸ | BLK | P51451 | 1/20 | 1.00 |
| ▸ | PRKAG1 | P54619 | 1/20 | 1.00 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 1.00 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Prexasertib SCHEMBL29371799 | 1.00 | CHEK1 (1.00) | CHEK1KCNH2NUAK1CHEK2RPS6KB1 | |
| Prexasertib SCHEMBL30517001 | 1.00 | CHEK1 (1.00) | CHEK1KCNH2NUAK1CHEK2RPS6KB1 | |
| Prexasertib SCHEMBL30528862 | 1.00 | CHEK1 (1.00) | CHEK1KCNH2NUAK1CHEK2RPS6KB1 | |
| Prexasertib SCHEMBL20668254 | 0.99 | CHEK1 (0.98) | CHEK1KCNH2NUAK1CHEK2RPS6KB1 | |
| Prexasertib SCHEMBL29838776 | 0.99 | CHEK1 (0.98) | CHEK1KCNH2NUAK1CHEK2RPS6KB1 | |
| Prexasertib SCHEMBL28527965 | 0.99 | CHEK1 (0.98) | CHEK1KCNH2NUAK1CHEK2RPS6KB1 | |
| Prexasertib SCHEMBL1971742 | 0.98 | CHEK1 (0.96) | CHEK1KCNH2NUAK1CHEK2RPS6KB1 | |
| Prexasertib SCHEMBL18955240 | 0.98 | CHEK1 (0.96) | CHEK1KCNH2NUAK1CHEK2RPS6KB1 | |
| Prexasertib SCHEMBL20591301 | 0.95 | CHEK1 (0.90) | CHEK1KCNH2NUAK1CHEK2RPS6KB1 | |
| Prexasertib SCHEMBL1971000 | 0.95 | CHEK1 (0.90) | CHEK1KCNH2NUAK1CHEK2RPS6KB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12558345-B2 | CHK1/2 inhibitors for use in the treatment of neuroblastomas and/or soft tissue sarcomas | ELI LILLY AND COMPANY (US) | 2026-02-24 | — | — | US | claimed |
| US-20240156808-A1 | Compositions and methods to improve the therapeutic benefit of suboptimally chemical compounds and biological therapies including substituted camptothecins such as irinotecan and topotecan for the treatment of benign and neoplastic hyperproliferative disease conditions, infections, inflammatory and immunological diseases | EDISON ONCOLOGY (US) | 2024-05-16 | — | — | US | claimed |
| EP-4297746-A2 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED COMPOUNDS AND THERAPIES FOR THE TREATMENT OF DISEASES | Edison Oncology (US) | 2024-01-03 | — | — | EP | claimed |
| US-20220378745-A1 | CHK1/2 INHIBITORS FOR USE IN THE TREATMENT OF NEUROBLASTOMAS AND/OR SOFT TISSUE SARCOMAS | ELI LILLY AND COMPANY | 2022-12-01 | — | — | US | claimed |
| US-11123326-B2 | CHK1/2 inhibitors and irinotecan for use in the treatment of rhabdomyosarcoma | ELI LILLY AND COMPANY (US) | 2021-09-21 | — | — | US | claimed |
| CN-108349948-B | 5- (5- (2- (3-aminopropoxy) -6-methoxyphenyl) -1H-pyrazol-3-ylamino) pyrazine-2-carbonitrile (S) -lactate monohydrate | 伊莱利利公司 | 2021-02-23 | — | — | CN | claimed |
| EP-3325468-B1 | CHK1/2 INHIBITORS FOR USE IN THE TREATMENT OF NEUROBLASTOMAS AND/OR SOFT TISSUE SARCOMAS | LILLY CO ELI (US) | 2020-11-11 | — | — | EP | claimed |
| EP-3386975-B1 | 5-(5-(2-(3-AMINOPROPOXY)-6-METHOXYPHENYL)-1H-PYRAZOL-3-YLAMINO)PYRAZINE-2-CARBONITRILE (S)-LACTATE MONOHYDRATE | LILLY CO ELI (US) | 2019-09-25 | — | — | EP | claimed |
| US-10189818-B2 | 5-(5-(2-(3-aminopropdoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitfile (S)-lactate monohydrate | ELI LILLY AND COMPANY (US) | 2019-01-29 | — | — | US | claimed |
| US-20180369202-A1 | CHK1/2 Inhibitors for Use in the Treatment of Neuroblastomas and/or Soft Tissue Sarcomas | ELI LILLY AND COMPANY | 2018-12-27 | — | — | US | claimed |
| EP-3386975-A1 | 5-(5-(2-(3-AMINOPROPOXY)-6-METHOXYPHENYL)-1H-PYRAZOL-3-YLAMINO)PYRAZINE-2-CARBONITRILE (S)-LACTATE MONOHYDRATE | Eli Lilly and Company (US) | 2018-10-17 | — | — | EP | claimed |
| EP-3325468-A1 | CHK1/2 INHIBITORS FOR USE IN THE TREATMENT OF NEUROBLASTOMAS AND/OR SOFT TISSUE SARCOMAS | Eli Lilly and Company (US) | 2018-05-30 | — | — | EP | claimed |
| WO-2017100071-A1 | 5-(5-(2-(3-AMINOPROPOXY)-6-METHOXYPHENYL)-1H-PYRAZOL-3-YLAMINO)PYRAZINE-2-CARBONITRILE (S)-LACTATE MONOHYDRATE | ELI LILLY AND COMPANY (US) | 2017-06-15 | — | — | WO | claimed |
| WO-2017015124-A1 | CHK1/2 INHIBITORS FOR USE IN THE TREATMENT OF NEUROBLASTOMAS AND/OR SOFT TISSUE SARCOMAS | ELI LILLY AND COMPANY (US) | 2017-01-26 | — | — | WO | claimed |
| EP-2379532-B1 | COMPOUNDS USEFUL FOR INHIBITING CHK1 | LILLY CO ELI (US) | 2013-02-20 | — | — | EP | claimed |
| US-8314108-B2 | 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitrile, pharmaceutically acceptable salts thereof, or solvate of salts | ELI LILLY AND COMPANY (US) | 2012-11-20 | — | — | US | claimed |
| EP-2379532-A1 | COMPOUNDS USEFUL FOR INHIBITING CHK1 | Eli Lilly and Company (US) | 2011-10-26 | — | — | EP | claimed |
| US-20110144126-A1 | COMPOUNDS USEFUL FOR INHIBITING CHK1 | ELI LILLY AND COMPANY | 2011-06-16 | — | — | US | claimed |
| WO-2010077758-A1 | COMPOUNDS USEFUL FOR INHIBITING CHK1 | ELI LILLY AND COMPANY (US) | 2010-07-08 | — | — | WO | claimed |
| US-12558345-B2 | CHK1/2 inhibitors for use in the treatment of neuroblastomas and/or soft tissue sarcomas | ELI LILLY AND COMPANY (US) | 2026-02-24 | — | — | US | disclosed |
| US-12558345-B2 | CHK1/2 inhibitors for use in the treatment of neuroblastomas and/or soft tissue sarcomas | ELI LILLY AND COMPANY (US) | 2026-02-24 | — | — | US | disclosed |
| US-20260009798-A1 | METHODS AND SYSTEMS FOR TREATING DISEASE USING AN ATR/CHK1 SIGNALING PATHWAY INHIBITOR | ACRIVON THERAPEUTICS INC (US) | 2026-01-08 | — | — | US | disclosed |
| US-20250340556-A1 | PYRIMIDOPYRIMIDONE COMPOUNDS AND METHODS OF USE THEREOF | SOLTEGO INC (US) | 2025-11-06 | — | — | US | disclosed |
| US-12433888-B1 | Methods and systems for treating disease using an ATR/Chk1 signaling pathway inhibitor | ACRIVON THERAPEUTICS, INC. (US) | 2025-10-07 | — | — | US | disclosed |
| US-20250134878-A1 | COMBINATION OF CHEK1 INHIBITOR AND TOP1 INHIBITOR FOR TREATING COLORECTAL CANCER | GENOME RESEARCH LIMITED (GB) | 2025-05-01 | — | — | US | disclosed |
| US-20240156808-A1 | Compositions and methods to improve the therapeutic benefit of suboptimally chemical compounds and biological therapies including substituted camptothecins such as irinotecan and topotecan for the treatment of benign and neoplastic hyperproliferative disease conditions, infections, inflammatory and immunological diseases | EDISON ONCOLOGY (US) | 2024-05-16 | — | — | US | disclosed |
| WO-2024015484-A2 | METHODS AND SYSTEMS FOR TREATING DISEASE USING AN ATR/CHK1 SIGNALING PATHWAY INHIBITOR | ACRIVON THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| WO-2024015484-A2 | METHODS AND SYSTEMS FOR TREATING DISEASE USING AN ATR/CHK1 SIGNALING PATHWAY INHIBITOR | ACRIVON THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| EP-4297746-A2 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED COMPOUNDS AND THERAPIES FOR THE TREATMENT OF DISEASES | Edison Oncology (US) | 2024-01-03 | — | — | EP | disclosed |
| US-11779859-B2 | Continuous production of active pharmaceutical ingredients | NEW JERSEY INSTITUTE OF TECHNOLOGY (US) | 2023-10-10 | — | — | US | disclosed |
| US-11779859-B2 | Continuous production of active pharmaceutical ingredients | NEW JERSEY INSTITUTE OF TECHNOLOGY (US) | 2023-10-10 | — | — | US | disclosed |
| WO-2023166078-A1 | COMBINATION TREATMENTS COMPRISING A CTPS1 INHIBITOR AND A CHEK1 INHIBITOR | STEP PHARMA S.A.S. (FR) | 2023-09-07 | — | — | WO | disclosed |
| WO-2023166078-A1 | COMBINATION TREATMENTS COMPRISING A CTPS1 INHIBITOR AND A CHEK1 INHIBITOR | STEP PHARMA S.A.S. (FR) | 2023-09-07 | — | — | WO | disclosed |
| US-11730734-B2 | Use of ATR and Chk1 inhibitor compounds | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-08-22 | — | — | US | disclosed |
| US-11730734-B2 | Use of ATR and Chk1 inhibitor compounds | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-08-22 | — | — | US | disclosed |
| US-20230218644-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF VIRAL INFECTIONS BY RESPIRATORY SYNDROME-RELATED CORONAVIRUS | EWHA WOMANS UNIVERSITY (KR) | 2023-07-13 | — | — | US | disclosed |
| US-20230218644-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF VIRAL INFECTIONS BY RESPIRATORY SYNDROME-RELATED CORONAVIRUS | EWHA WOMANS UNIVERSITY (KR) | 2023-07-13 | — | — | US | disclosed |
| US-11634424-B2 | Diazaindole derivative and use thereof as CHK1 inhibitor | MEDSHINE DISCOVERY INC. (CN) | 2023-04-25 | — | — | US | disclosed |
| US-11564920-B2 | 5-heteroaryl-1H-pyrazol-3-amine derivative | Sumitomo Pharma Co., Ltd. (JP) | 2023-01-31 | — | — | US | disclosed |
| US-20230025065-A1 | 5-HETEROARYL-1H-PYRAZOL-3-AMINE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2023-01-26 | — | — | US | disclosed |
| US-20230017858-A1 | DIAZAINDOLE DERIVATIVE AND USE THEREOF AS CHK1 INHIBITOR | Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. (CN) | 2023-01-19 | — | — | US | disclosed |
| US-20220378745-A1 | CHK1/2 INHIBITORS FOR USE IN THE TREATMENT OF NEUROBLASTOMAS AND/OR SOFT TISSUE SARCOMAS | ELI LILLY AND COMPANY | 2022-12-01 | — | — | US | disclosed |
| US-20220378745-A1 | CHK1/2 INHIBITORS FOR USE IN THE TREATMENT OF NEUROBLASTOMAS AND/OR SOFT TISSUE SARCOMAS | ELI LILLY AND COMPANY | 2022-12-01 | — | — | US | disclosed |
| US-20220378745-A1 | CHK1/2 INHIBITORS FOR USE IN THE TREATMENT OF NEUROBLASTOMAS AND/OR SOFT TISSUE SARCOMAS | ELI LILLY AND COMPANY | 2022-12-01 | — | — | US | disclosed |
| US-20220176270-A1 | Continuous Production of Active Pharmaceutical Ingredients | NEW JERSEY INSTITUTE OF TECHNOLOGY (US) | 2022-06-09 | — | — | US | disclosed |
| US-20220133693-A1 | THERAPEUTIC TREATMENT OF MICROSATELLITE UNSTABLE CANCERS | THE BROAD INSTITUTE, INC. (US) | 2022-05-05 | — | — | US | disclosed |
| US-20220107328-A1 | METHODS OF TREATING LIVER DISEASES | CAMP4 THERAPEUTICS CORPORATION | 2022-04-07 | — | — | US | disclosed |
| WO-2021262874-A1 | USE OF A DHODH INHIBITOR COMPOUND IN COMBINATION CANCER THERAPY | SERVIER PHARMACEUTICALS , LLC (US) | 2021-12-30 | — | — | WO | disclosed |
| US-11123326-B2 | CHK1/2 inhibitors and irinotecan for use in the treatment of rhabdomyosarcoma | ELI LILLY AND COMPANY (US) | 2021-09-21 | — | — | US | disclosed |
| US-11123326-B2 | CHK1/2 inhibitors and irinotecan for use in the treatment of rhabdomyosarcoma | ELI LILLY AND COMPANY (US) | 2021-09-21 | — | — | US | disclosed |
| EP-3836929-A1 | METHODS OF TREATING LIVER DISEASES | Camp4 Therapeutics Corporation (US) | 2021-06-23 | — | — | EP | disclosed |
| WO-2021104461-A1 | DIAZAINDOLE DERIVATIVE AND USE THEREOF AS CHK1 INHIBITOR | 南京明德新药研发有限公司 | 2021-06-03 | — | — | WO | disclosed |
| CN-108349948-B | 5- (5- (2- (3-aminopropoxy) -6-methoxyphenyl) -1H-pyrazol-3-ylamino) pyrazine-2-carbonitrile (S) -lactate monohydrate | 伊莱利利公司 | 2021-02-23 | — | — | CN | disclosed |
| CN-108349948-B | 5- (5- (2- (3-aminopropoxy) -6-methoxyphenyl) -1H-pyrazol-3-ylamino) pyrazine-2-carbonitrile (S) -lactate monohydrate | 伊莱利利公司 | 2021-02-23 | — | — | CN | disclosed |
| CN-108349948-B | 5- (5- (2- (3-aminopropoxy) -6-methoxyphenyl) -1H-pyrazol-3-ylamino) pyrazine-2-carbonitrile (S) -lactate monohydrate | 伊莱利利公司 | 2021-02-23 | — | — | CN | disclosed |
| EP-3325468-B1 | CHK1/2 INHIBITORS FOR USE IN THE TREATMENT OF NEUROBLASTOMAS AND/OR SOFT TISSUE SARCOMAS | LILLY CO ELI (US) | 2020-11-11 | — | — | EP | disclosed |
| EP-3325468-B1 | CHK1/2 INHIBITORS FOR USE IN THE TREATMENT OF NEUROBLASTOMAS AND/OR SOFT TISSUE SARCOMAS | LILLY CO ELI (US) | 2020-11-11 | — | — | EP | disclosed |
| US-20200208128-A1 | METHODS OF TREATING LIVER DISEASES | CAMP4 THERAPEUTICS CORPORATION | 2020-07-02 | — | — | US | disclosed |
| CN-111094581-A | Methods of treating liver disease | 4阵营疗法公司 | 2020-05-01 | — | — | CN | disclosed |
| WO-2020037069-A1 | METHODS OF TREATING LIVER DISEASES | CAMP4 THERAPEUTICS CORPORATION (US) | 2020-02-20 | — | — | WO | disclosed |
| US-20190314528-A1 | TARGETED THERAPEUTICS | SYNTA PHARMACEUTICALS CORP. | 2019-10-17 | — | — | US | disclosed |
| US-20190314528-A1 | TARGETED THERAPEUTICS | SYNTA PHARMACEUTICALS CORP. | 2019-10-17 | — | — | US | disclosed |
| EP-3389660-B1 | COMBINATION THERAPY FOR CANCER | LILLY CO ELI (US) | 2019-10-16 | — | — | EP | disclosed |
| EP-3389660-B1 | COMBINATION THERAPY FOR CANCER | LILLY CO ELI (US) | 2019-10-16 | — | — | EP | disclosed |
| EP-3386975-B1 | 5-(5-(2-(3-AMINOPROPOXY)-6-METHOXYPHENYL)-1H-PYRAZOL-3-YLAMINO)PYRAZINE-2-CARBONITRILE (S)-LACTATE MONOHYDRATE | LILLY CO ELI (US) | 2019-09-25 | — | — | EP | disclosed |
| EP-3386975-B1 | 5-(5-(2-(3-AMINOPROPOXY)-6-METHOXYPHENYL)-1H-PYRAZOL-3-YLAMINO)PYRAZINE-2-CARBONITRILE (S)-LACTATE MONOHYDRATE | LILLY CO ELI (US) | 2019-09-25 | — | — | EP | disclosed |
| US-20190269682-A1 | USE OF ATR AND CHK1 INHIBITOR COMPOUNDS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-09-05 | — | — | US | disclosed |
| US-10376598-B2 | Targeted therapeutics | MADRIGAL PHARMACEUTICALS, INC. (US) | 2019-08-13 | — | — | US | disclosed |
| US-10376598-B2 | Targeted therapeutics | MADRIGAL PHARMACEUTICALS, INC. (US) | 2019-08-13 | — | — | US | disclosed |
| WO-2018237291-A9 | SIGNALING CENTERS OF ERYTHROID DIFFERENTIATION | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2019-04-04 | — | — | WO | disclosed |
| EP-3461480-A1 | COMBINATION OF A DNA DAMAGE RESPONSE CELL CYCLE CHECKPOINT INHIBITORS AND BELINOSTAT FOR TREATING CANCER | ONXEO (FR) | 2019-04-03 | — | — | EP | disclosed |
| US-10189818-B2 | 5-(5-(2-(3-aminopropdoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitfile (S)-lactate monohydrate | ELI LILLY AND COMPANY (US) | 2019-01-29 | — | — | US | disclosed |
| US-10189818-B2 | 5-(5-(2-(3-aminopropdoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitfile (S)-lactate monohydrate | ELI LILLY AND COMPANY (US) | 2019-01-29 | — | — | US | disclosed |
| US-10189818-B2 | 5-(5-(2-(3-aminopropdoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitfile (S)-lactate monohydrate | ELI LILLY AND COMPANY (US) | 2019-01-29 | — | — | US | disclosed |
| US-10189818-B2 | 5-(5-(2-(3-aminopropdoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitfile (S)-lactate monohydrate | ELI LILLY AND COMPANY (US) | 2019-01-29 | — | — | US | disclosed |
| US-20190002886-A1 | SIGNALING CENTERS OF ERYTHROID DIFFERENTIATION | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2019-01-03 | — | — | US | disclosed |
| US-20180369202-A1 | CHK1/2 Inhibitors for Use in the Treatment of Neuroblastomas and/or Soft Tissue Sarcomas | ELI LILLY AND COMPANY | 2018-12-27 | — | — | US | disclosed |
| EP-3389660-A1 | COMBINATION THERAPY FOR CANCER | Eli Lilly and Company (US) | 2018-10-24 | — | — | EP | disclosed |
| EP-3386975-A1 | 5-(5-(2-(3-AMINOPROPOXY)-6-METHOXYPHENYL)-1H-PYRAZOL-3-YLAMINO)PYRAZINE-2-CARBONITRILE (S)-LACTATE MONOHYDRATE | Eli Lilly and Company (US) | 2018-10-17 | — | — | EP | disclosed |
| EP-3386975-A1 | 5-(5-(2-(3-AMINOPROPOXY)-6-METHOXYPHENYL)-1H-PYRAZOL-3-YLAMINO)PYRAZINE-2-CARBONITRILE (S)-LACTATE MONOHYDRATE | Eli Lilly and Company (US) | 2018-10-17 | — | — | EP | disclosed |
| EP-3386975-A1 | 5-(5-(2-(3-AMINOPROPOXY)-6-METHOXYPHENYL)-1H-PYRAZOL-3-YLAMINO)PYRAZINE-2-CARBONITRILE (S)-LACTATE MONOHYDRATE | Eli Lilly and Company (US) | 2018-10-17 | — | — | EP | disclosed |
| WO-2018136010-A1 | COMBINATION THERAPY | ASLAN PHARMACEUTICALS PTE LTD (SG) | 2018-07-26 | — | — | WO | disclosed |
| EP-3325468-A1 | CHK1/2 INHIBITORS FOR USE IN THE TREATMENT OF NEUROBLASTOMAS AND/OR SOFT TISSUE SARCOMAS | Eli Lilly and Company (US) | 2018-05-30 | — | — | EP | disclosed |
| EP-3325468-A1 | CHK1/2 INHIBITORS FOR USE IN THE TREATMENT OF NEUROBLASTOMAS AND/OR SOFT TISSUE SARCOMAS | Eli Lilly and Company (US) | 2018-05-30 | — | — | EP | disclosed |
| WO-2018049400-A1 | USE OF ATR AND CHK1 INHIBITOR COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2018-03-15 | — | — | WO | disclosed |
| WO-2017200492-A1 | METHOD OF TREATING CANCER | ASLAN PHARMACEUTICALS PTE LTD (SG) | 2017-11-23 | — | — | WO | disclosed |
| WO-2017133517-A1 | PHOSPHAMIDE DERIVATIVE, METHOD FOR MANUFACTURING THE SAME, AND USES THEREOF | 四川海思科制药有限公司 | 2017-08-10 | — | — | WO | disclosed |
| WO-2017105982-A1 | COMBINATION THERAPY FOR CANCER | ELI LILLY AND COMPANY (US) | 2017-06-22 | — | — | WO | disclosed |
| WO-2017105982-A1 | COMBINATION THERAPY FOR CANCER | ELI LILLY AND COMPANY (US) | 2017-06-22 | — | — | WO | disclosed |
| WO-2017100071-A1 | 5-(5-(2-(3-AMINOPROPOXY)-6-METHOXYPHENYL)-1H-PYRAZOL-3-YLAMINO)PYRAZINE-2-CARBONITRILE (S)-LACTATE MONOHYDRATE | ELI LILLY AND COMPANY (US) | 2017-06-15 | — | — | WO | disclosed |
| WO-2017100071-A1 | 5-(5-(2-(3-AMINOPROPOXY)-6-METHOXYPHENYL)-1H-PYRAZOL-3-YLAMINO)PYRAZINE-2-CARBONITRILE (S)-LACTATE MONOHYDRATE | ELI LILLY AND COMPANY (US) | 2017-06-15 | — | — | WO | disclosed |
| WO-2017100071-A1 | 5-(5-(2-(3-AMINOPROPOXY)-6-METHOXYPHENYL)-1H-PYRAZOL-3-YLAMINO)PYRAZINE-2-CARBONITRILE (S)-LACTATE MONOHYDRATE | ELI LILLY AND COMPANY (US) | 2017-06-15 | — | — | WO | disclosed |
| WO-2017015124-A1 | CHK1/2 INHIBITORS FOR USE IN THE TREATMENT OF NEUROBLASTOMAS AND/OR SOFT TISSUE SARCOMAS | ELI LILLY AND COMPANY (US) | 2017-01-26 | — | — | WO | disclosed |
| WO-2017015124-A1 | CHK1/2 INHIBITORS FOR USE IN THE TREATMENT OF NEUROBLASTOMAS AND/OR SOFT TISSUE SARCOMAS | ELI LILLY AND COMPANY (US) | 2017-01-26 | — | — | WO | disclosed |
| US-20160375142-A1 | TARGETED THERAPEUTICS | MADRIGAL PHARMACEUTICALS, INC. | 2016-12-29 | — | — | US | disclosed |
| WO-2015066053-A2 | TARGETED THERAPEUTICS | SYNTA PHARMACEUTICALS CORP. (US) | 2015-05-07 | — | — | WO | disclosed |
| WO-2015066053-A2 | TARGETED THERAPEUTICS | SYNTA PHARMACEUTICALS CORP. (US) | 2015-05-07 | — | — | WO | disclosed |
| EP-2379532-B1 | COMPOUNDS USEFUL FOR INHIBITING CHK1 | LILLY CO ELI (US) | 2013-02-20 | — | — | EP | disclosed |
| US-8314108-B2 | 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitrile, pharmaceutically acceptable salts thereof, or solvate of salts | ELI LILLY AND COMPANY (US) | 2012-11-20 | — | — | US | disclosed |
| US-8314108-B2 | 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitrile, pharmaceutically acceptable salts thereof, or solvate of salts | ELI LILLY AND COMPANY (US) | 2012-11-20 | — | — | US | disclosed |
| US-8314108-B2 | 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitrile, pharmaceutically acceptable salts thereof, or solvate of salts | ELI LILLY AND COMPANY (US) | 2012-11-20 | — | — | US | disclosed |
| US-8314108-B2 | 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitrile, pharmaceutically acceptable salts thereof, or solvate of salts | ELI LILLY AND COMPANY (US) | 2012-11-20 | — | — | US | disclosed |
| EP-2379532-A1 | COMPOUNDS USEFUL FOR INHIBITING CHK1 | Eli Lilly and Company (US) | 2011-10-26 | — | — | EP | disclosed |
| US-20110144126-A1 | COMPOUNDS USEFUL FOR INHIBITING CHK1 | ELI LILLY AND COMPANY | 2011-06-16 | — | — | US | disclosed |
| US-20110144126-A1 | COMPOUNDS USEFUL FOR INHIBITING CHK1 | ELI LILLY AND COMPANY | 2011-06-16 | — | — | US | disclosed |
| US-20110144126-A1 | COMPOUNDS USEFUL FOR INHIBITING CHK1 | ELI LILLY AND COMPANY | 2011-06-16 | — | — | US | disclosed |
| WO-2010077758-A1 | COMPOUNDS USEFUL FOR INHIBITING CHK1 | ELI LILLY AND COMPANY (US) | 2010-07-08 | — | — | WO | disclosed |
| WO-2010077758-A1 | COMPOUNDS USEFUL FOR INHIBITING CHK1 | ELI LILLY AND COMPANY (US) | 2010-07-08 | — | — | WO | disclosed |
| WO-2010077758-A1 | COMPOUNDS USEFUL FOR INHIBITING CHK1 | ELI LILLY AND COMPANY (US) | 2010-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (27 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11564920-B2 | 5-heteroaryl-1H-pyrazol-3-amine derivative | CHEK1, CHEK2, RB1 | CHEK1 1/4885CHEK2 2/4885KCNH2 2700/4885 |
| US-20250340556-A1 | PYRIMIDOPYRIMIDONE COMPOUNDS AND METHODS OF USE THEREOF | SIK2, SIK1, SIK3 | CHEK1 170/4885CHEK2 117/4885KCNH2 1294/4885 |
| US-20220176270-A1 | Continuous Production of Active Pharmaceutical Ingredients | SAMM50, VMA21, CYP3A4 | CHEK1 4764/4885CHEK2 4854/4885KCNH2 2685/4885 |
| US-20190269682-A1 | USE OF ATR AND CHK1 INHIBITOR COMPOUNDS | CHEK1, ATR, CHEK2 | CHEK1 1/4885CHEK2 3/4885KCNH2 3803/4885 |
| US-20180369202-A1 | CHK1/2 Inhibitors for Use in the Treatment of Neuroblastomas and/or Soft Tissue Sarcomas | CHEK1, CHEK2, PLK1 | CHEK1 1/4885CHEK2 2/4885KCNH2 3234/4885 |
| US-20230017858-A1 | DIAZAINDOLE DERIVATIVE AND USE THEREOF AS CHK1 INHIBITOR | CHEK1, CHEK2, DDB1 | CHEK1 1/4885CHEK2 2/4885KCNH2 4190/4885 |
| US-20220133693-A1 | THERAPEUTIC TREATMENT OF MICROSATELLITE UNSTABLE CANCERS | MSH2, MSH6, PMS2 | CHEK1 34/4885CHEK2 33/4885KCNH2 4691/4885 |
| US-20110144126-A1 | COMPOUNDS USEFUL FOR INHIBITING CHK1 | CHEK1, CHEK2, PLK1 | CHEK1 1/4885CHEK2 2/4885KCNH2 3087/4885 |
| US-10376598-B2 | Targeted therapeutics | CDC37, HSP90AB1, HSP90B1 | CHEK1 2206/4885CHEK2 2060/4885KCNH2 4790/4885 |
| US-20230025065-A1 | 5-HETEROARYL-1H-PYRAZOL-3-AMINE DERIVATIVE | CHEK1, CHEK2, RB1 | CHEK1 1/4885CHEK2 2/4885KCNH2 2700/4885 |
| US-20240156808-A1 | Compositions and methods to improve the therapeutic benefit of suboptimally chemical compounds and biological therapies including substituted camptothecins such as irinotecan and topotecan for the treatment of benign and neoplastic hyperproliferative disease conditions, infections, inflammatory and immunological diseases | TOP2A, TOP2B, TOP1 | CHEK1 53/4885CHEK2 87/4885KCNH2 4497/4885 |
| US-20220378745-A1 | CHK1/2 INHIBITORS FOR USE IN THE TREATMENT OF NEUROBLASTOMAS AND/OR SOFT TISSUE SARCOMAS | CHEK1, CHEK2, PLK1 | CHEK1 1/4885CHEK2 2/4885KCNH2 3382/4885 |
| US-20190314528-A1 | TARGETED THERAPEUTICS | CDC37, HSP90AB1, HSP90B1 | CHEK1 2206/4885CHEK2 2060/4885KCNH2 4790/4885 |
| US-20200208128-A1 | METHODS OF TREATING LIVER DISEASES | LIPC, PNPLA2, PNLIP | CHEK1 4684/4885CHEK2 4649/4885KCNH2 4769/4885 |
| US-12433888-B1 | Methods and systems for treating disease using an ATR/Chk1 signaling pathway inhibitor | CHEK1, WEE1, WEE2 | CHEK1 1/4885CHEK2 4/4885KCNH2 4610/4885 |
| US-20220107328-A1 | METHODS OF TREATING LIVER DISEASES | PNPLA2, LIPC, PNLIP | CHEK1 4731/4885CHEK2 4714/4885KCNH2 4822/4885 |
| US-20160375142-A1 | TARGETED THERAPEUTICS | CDC37, HSP90AB1, HSP90B1 | CHEK1 2206/4885CHEK2 2060/4885KCNH2 4790/4885 |
| US-20230218644-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF VIRAL INFECTIONS BY RESPIRATORY SYNDROME-RELATED CORONAVIRUS | ACE2, ACE, TMPRSS2 | CHEK1 191/4885CHEK2 447/4885KCNH2 1711/4885 |
| US-20250134878-A1 | COMBINATION OF CHEK1 INHIBITOR AND TOP1 INHIBITOR FOR TREATING COLORECTAL CANCER | TOP1, CHEK1, CHEK2 | CHEK1 2/4885CHEK2 3/4885KCNH2 4545/4885 |
| US-10189818-B2 | 5-(5-(2-(3-aminopropdoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitfile (S)-lactate monohydrate | CHEK2, CHEK1, LDHA | CHEK1 2/4885CHEK2 1/4885KCNH2 3957/4885 |
| US-11634424-B2 | Diazaindole derivative and use thereof as CHK1 inhibitor | CHEK1, CHEK2, DDB1 | CHEK1 1/4885CHEK2 2/4885KCNH2 4190/4885 |
| US-20260009798-A1 | METHODS AND SYSTEMS FOR TREATING DISEASE USING AN ATR/CHK1 SIGNALING PATHWAY INHIBITOR | CHEK1, CHEK2, CKS1B | CHEK1 1/4885CHEK2 2/4885KCNH2 4792/4885 |
| US-20190002886-A1 | SIGNALING CENTERS OF ERYTHROID DIFFERENTIATION | EPOR, EBP, HCLS1 | CHEK1 3405/4885CHEK2 3100/4885KCNH2 4672/4885 |
| US-12558345-B2 | CHK1/2 inhibitors for use in the treatment of neuroblastomas and/or soft tissue sarcomas | CHEK1, CHEK2, MRE11 | CHEK1 1/4885CHEK2 2/4885KCNH2 3998/4885 |
| US-11730734-B2 | Use of ATR and Chk1 inhibitor compounds | CHEK1, ATR, CHEK2 | CHEK1 1/4885CHEK2 3/4885KCNH2 3803/4885 |
| US-11779859-B2 | Continuous production of active pharmaceutical ingredients | SAMM50, VMA21, CYP3A4 | CHEK1 4764/4885CHEK2 4854/4885KCNH2 2685/4885 |
| US-11123326-B2 | CHK1/2 inhibitors and irinotecan for use in the treatment of rhabdomyosarcoma | CHEK1, CHEK2, TOP2A | CHEK1 1/4885CHEK2 2/4885KCNH2 3724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.